---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-26-000024"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:14:14.857251+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma Q1 revenue $1.1B (+19% YoY), EPS $4.43 GAAP / $6.34 adj; Zanidatamab PDUFA Aug 25

## Summary
- Total revenues $1.1B (+19% YoY); GAAP EPS $4.43, non-GAAP adj. EPS $6.34; operating cash flow $408M.
- Xywav net product sales $408M (+18% YoY) with 425 net patient adds; Epidiolex grew 15% YoY.
- Zanidatamab sBLA for HER2+ 1L GEA granted Priority Review; PDUFA date Aug 25, 2026.
- Company reaffirms 2026 revenue and expense guidance.

## SEC filing metadata
- accession: 0001232524-26-000024
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/0001232524-26-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/jazz-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-26-000024
- JSON: https://secwatch.observer/filing/0001232524-26-000024.json
- Plain text: https://secwatch.observer/filing/0001232524-26-000024.txt

## Source-grounded claims
- claim_id: 3513953057bb0c3750e66f34eb054643cfb25ec4
  claim: Jazz Pharmaceuticals plc reported first quarter of 2026 (1Q26) results: revenue $1.1 billion, EPS $4.43 / $6.34. Guidance reaffirmed.
  evidence_excerpt: filing. --- EX-99.1 (EX-99.1) --- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results – Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav ® revenues grew 18% YoY with 425 net patient adds – – Epidiolex ®
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/0001232524-26-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.